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ABSTRACT
Objective To evaluate the association between arsenic
exposure and mortality from cardiovascular disease and
to assess whether cigarette smoking influences the
association.
Design Prospective cohort study with arsenic exposure
measured in drinking water from wells and urine.
Setting General population in Araihazar, Bangladesh.
Participants 11746 men and women who provided urine
samplesin2000andwerefollowedupforanaverageof6.
6 years.
Main outcome measure Death from cardiovascular
disease.
Results 198 people died from diseases of circulatory
system, accounting for 43% of total mortality in the
population. The mortality rate for cardiovascular disease
was 214.3 per 100000 person years in people drinking
watercontaining<12.0µg/Larsenic,comparedwith271.1
per 100000 person years in people drinking water with
≥12.0 µg/L arsenic. There was a dose-response relation
between exposure to arsenic in well water assessed at
baseline and mortality from ischaemic heart disease and
other heart disease; the hazard ratios in increasing
quarters of arsenic concentration in well water (0.1-12.0,
12.1-62.0, 62.1-148.0, and 148.1-864.0 µg/L) were 1.00
(reference), 1.22 (0.65 to 2.32), 1.35 (0.71 to 2.57), and
1.92 (1.07 to 3.43) (P=0.0019 for trend), respectively,
after adjustment for potentialconfounders including age,
sex, smoking status, educational attainment, body mass
index(BMI),andchangesinurinaryarsenicconcentration
since baseline. Similar associations were observed when
baseline total urinary arsenic was used as the exposure
variable and for mortality from ischaemic heart disease
specifically. The data indicate a significant synergistic
interaction between arsenic exposure and cigarette
smoking in mortality from ischaemic heart disease and
other heart disease. In particular, the hazard ratio for the
joint effect of a moderate level of arsenic exposure
(middle third of well arsenic concentration 25.3-
114.0 µg/L, mean 63.5 µg/L) and cigarette smoking on
mortality from heart disease was greater than the sum of
the hazard ratios associated with their individual effect
(relative excess risk for interaction 1.56, 0.05 to 3.14;
P=0.010).
Conclusions Exposure to arsenic in drinking water is
adversely associated with mortality from heart disease,
especially among smokers.
INTRODUCTION
Arsenic is a natural element of the earth’s crust, which
can enter drinking water supplies from natural depos-
its. Raised concentrations of arsenic in groundwater
poseapublichealththreattomillionsofpeopleworld-
wide, including 13 million residents in the United
States.
1 Although the International Agency for
Research on Cancer has classified arsenic as a group
1 human carcinogen, evidence of other effects on
health, including cardiovascular effects, has not been
well established.
23
High levels of arsenic exposure (>500 µg/L) in
drinking water have been related to increased risks in
many cardiovascular diseases, including
hypertension,
45ischaemic heart disease,
67and carotid
atherosclerosis
8 in a series of retrospective cohort stu-
dies in south western Taiwan and Chile.
68-11 Several
studies in the United States and Spain have reported
positive associations between arsenic exposure at
lower concentrations (<300 µg/L) and mortality from
coronary heart disease, hypertension, hypertensive
heart disease, or diseases of arteries, arterioles, and
capillaries.
12-15 The use of ecological study designs
12-14
or exposure measured at the group level, however,
1Department of Environmental
Medicine, New York University
School of Medicine, New York, NY
10016, USA
2Department of Environmental
Health Sciences, Mailman School
of Public Health, Columbia
University, New York
3Departments of Health Studies,
Medicine and Human Genetics
and Comprehensive Cancer
Center, University of Chicago,
Chicago, IL 60637
4University of Chicago and
Columbia University Research
Project Office, Dhaka, Bangladesh
5Lamont-Doherty Earth
Observatory of Columbia
University, Palisades, New York
Correspondence to: Y Chen
yu.chen@nyumc.org, H Ahsan
habib@uchicago.edu
Cite this as: BMJ 2011;342:d2431
doi:10.1136/bmj.d2431
BMJ | ONLINE FIRST | bmj.com page 1 of 11limits the causal inference in studies that investigated
effects of lower concentrations. In addition, previous
studies have reported that the risks associated with
arsenic exposure for skin lesions,
1617 bladder
cancer,
1819 and lung cancer
20 are higher among smo-
kers. Studies examining the potential interaction
between arsenic exposure and cigarette smoking in
the risk of cardiovascular disease, however, are lack-
ing. As cardiovascular disease leads to about a third
of the mortality in the world, a small increased risk
associated with arsenic exposure would translate into
alargenumberofexcessdeathsintheexposedpopula-
tionandcouldbeofmajorimportancetopublichealth.
Prospective studies with multiple exposure measures
andinformationonsusceptiblefactorssuchascigarette
smoking at the individual level are needed.
The contamination of groundwater with arsenic in
Bangladesh has been recognised as a massive public
health hazard.
2122 An estimated 57 million people
have been chronically exposed to groundwater with
arsenic concentrations exceeding the WHO
standard.
23Toevaluatethe healtheffectsofsuchexpo-
sure, in 2000 we established a cohort study in Araiha-
zar, Bangladesh. The study, with participants exposed
to arsenic concentrations in water from drinking wells
from0.1µg/Lto864µg/L(mean99µg/L)atbaseline,
provides us with a unique opportunity to evaluate the
cardiovascular effects of exposure at low to moderate
concentrations.
We tested the hypothesis that exposure to arsenic,
measured in both water and urine, is associated with
mortality from cardiovascular disease. We also tested
the hypotheses that cigarette smoking increases the
susceptibility to the cardiovascular effects of arsenic
exposure.
METHODS
The study is an ongoing prospective cohort study in
Araihazar, Bangladesh. Details of the methods have
been presented elsewhere.
2425 Briefly, before partici-
pants were recruited, water samples and their geogra-
phical coordinates were collected for 5966 contiguous
wells in a well defined area of 25 km
2. Between Octo-
ber 2000 and May 2002, we recruited 11746 men and
women who met the following eligibility criteria: mar-
ried(toreducelosstofollow-up)andagedbetween18-
75; living in the study area for at least five years before
recruitment; and primary user of one of the 5966 tube
wells, designated as the “index” well, for at least three
years.
24Theresponseratewas97.5%.
24Informationon
demographicand lifestyle variableswascollected with
a standardised questionnaire at baseline and follow-up
visits.Trainedcliniciansmeasuredbloodpressurewith
an automatic sphygmomanometer.
26 Participants who
saidthataphysicianhadgiventhemadiagnosisofdia-
betes before baseline were retrospectively identified
from data collected at the first follow-up.
27 The com-
parison between self reported diabetes status and test
resultsforbloodglycosylated haemoglobin andgluco-
suria suggested validity of the questionnaire data.
27
The cohort is being actively followed with a personal
visit at two year intervals, which includes a physical
examination and structured interview conducted by
trained physicians following the same procedures
used in the baseline interview. The present study
includes data from the first (September 2002 to May
2004), second (June 2004 to August 2006), and third
(January 2007 to March 2009) follow-up. In addition,
a field clinic was established for cohort participants for
follow-up between their biennial visits.
24
Assessment of causes of deaths
Our outcome of interest was deaths from cardio-
vascular disease, defined as deaths from disease of cir-
culatorysystem(ICD-10(internationalclassificationof
diseases, 10th revision) codes I00-I99) in cohort parti-
cipants from baseline to 18 March 2009 (end of the
third follow-up). Details of the methods for the assess-
ment of causes of deaths are described elsewhere.
28
Briefly, we adapted a validated verbal autopsy proce-
dure, developed by the International Centre for Diar-
rhea Disease Research, Bangladesh, in collaboration
with the World Health Organization, to ascertain the
causes of deaths. During the follow-up, on receipt of a
reportofdeathfromfamilyorneighbours,astudyphy-
sicianandatrainedsocialworkeradministeredthever-
bal autopsy form to the next of kin. Medical records
from physicians who had treated the dead person
were collected. For deaths in hospital, information on
death certificates and biopsies was ascertained. Each
month an outcome assessment committee, consisting
of physicians and consulting medical specialists
blinded to the exposure status, reviewed the data.
Causes of deaths were coded according to the WHO
classification
29 and ICD-10.
30 The International Cen-
tre for Diarrhea Disease Research, Bangladesh, has
used this method to ascertain causes of deaths since
1971
3132 and documented an overall 95% specificity,
with a 85% sensitivity for deaths from cancer and up
to 85% sensitivity for cardiovascular deaths.
33
Measurements of arsenic exposure
At baseline, water samples from all 5966 tube wells in
the study area were collected in 50 mL acid washed
tubes after the well was pumped for five minutes.
3435
Total arsenic concentration was determined by gra-
phite furnace atomic absorption spectrometry with a
Hitachi Z-8200 system.
36 Samples that fell below the
detection limit (5 μg/L) were subsequently analysed
by inductively coupled plasma mass spectrometry,
with a detection limit of 0.1 μg/L.
37 Analyses for time
series samples collected from a subset of tube wells in
thestudyareashowedlittlevariationinarsenicconcen-
trationovertime.
36Wethereforeusedthesamearsenic
concentrationfora givenwellastheexposurelevelfor
its users who were recruited in the study, even if they
were included at different time frames.
All participants were primary users of one of the 5966
tube wells; 89% of study participants shared tube wells
with up to five other study participants, while the 14%
remaining shared their wells with 6-13 others.
38 Using
b a s e l i n ed a t a ,w ed e r i v e dat i m ew e i g h t e da r s e n i c
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well arsenic concentrations (see equation A in fig 1).
38
The average duration of use of wells for wells with a
known arsenic concentration accounted for 25% of life-
time (>8 years) for both sexes.
38
Spot urine samples were collected from 11224
(95.6%) of 11746 interviewed participants at baseline,
11109 (98.1%) of 11323 at the first follow-up, and
10726 (98.1%) of 10934 at the second follow-up. Total
urinaryarsenicconcentrationwasmeasuredbygraphite
furnaceatomic absorptionspectrometry,with a Perkin-
Elmer AAnalyst 600 graphite furnace system with a
detection limit of 2 μg/L, as previously described.
39
Urinary creatinine was analysed with a method based
on the Jaffe reaction for adjustment of urinary total
arsenic concentration.
40 We implemented an arsenic
mitigation programme in the study area at baseline to
promote switching to safe wells—that is, to wells yield-
ing water with an arsenic concentration lower than the
Bangladeshstandardof50µg/L.
41Asexposureconcen-
trationmightchangeinsomeparticipantsfrombaseline,
we calculated changes in urinary arsenic between visits
using urinary creatinine adjusted arsenic.
Measurements of dietary intakes
Dietary intakes were measured at baseline with a vali-
dated semiquantitative food frequency questionnaire
designed for the study population. Detailed informa-
tion on the design and the validation of the food fre-
quency questionnaire has been published elsewhere.
42
Briefly, to assess the validity of the questionnaire,
trained interviewers completed two seven-day food
diaries in two separate seasons for 189 participants.
The results of the validation study indicate that the
food frequency questionnaire provides reasonably
valid measurements for long term dietary intakes of
common foods, macronutrients, and common
micronutrients.
42
Statistical analysis
Primary objectives: association between arsenic exposure
and mortality from cardiovascular disease
Wecomputedperson timefrom baselineto the date of
death from any cause or the date of the third active
follow-up visit, whichever came first. We used Cox
proportionalhazardsregressiontocomputethehazard
ratiosfordeathsfromdiseaseofthecirculatorysystem,
ischaemic heart disease, and cerebrovascular disease,
in relation to quarters of baseline well arsenic concen-
tration, time weighted arsenic concentration, baseline
urinary arsenic concentration, and changes in urinary
arsenic between visits. We also estimated the hazard
ratios in relation to 1 SD increase in well arsenic or
urinary arsenic for better interpretation of the effect
estimates. The assumption of proportional hazards
was examined by testing the cross product terms
between covariate variables and log function of survi-
val time,and P valuesforallthe termswere >0.10. We
examined the assumption of non-linear effect of
arsenic exposure by including higher order poly-
nomial terms for arsenic exposure variables in the
models, and there was no indication of any non-linear
relation. Because deaths from other forms of heart dis-
ease were often a consequence of previous ischaemic
heart disease in our study population, and patterns of
the hazard ratios were similar for ischaemic heart dis-
easeandotherformsofheartdisease,we estimatedthe
hazardratiosforthecombinedcategoryandforischae-
mic heart disease separately.
We first adjusted for age at baseline and sex. A sec-
ond model was constructed to additionally adjust for a
priori defined potential confounders, including base-
line educational level (years), body mass index
(BMI), and smoking status (never, past, and current),
all of which are known risk factors for cardiovascular
diseasethatmightberelatedtothedistributionofbase-
line arsenic exposure or influence health effects of
arsenicexposureinourstudypopulation.
163843Appen-
dix 1 on bmj.com shows the associations between
potential confounders and well arsenic concentration.
We included changes in urinary arsenic between visits
as a time dependent variable. For instance, for deaths
fromcardiovasculardiseasethatoccurredbetweenthe
first and second follow-up, we used the difference in
urinary creatinine adjusted arsenic (urinary arsenic
concentration with adjustment for creatinine in the
urine) between the baseline and first follow-up as the
relevant changes in urinary arsenic. Missing data
(<2%)werecodedbyusingdummyvariables,allowing
participants with one or more missing potential con-
founders to be included in the analyses under a “miss-
ing at random” assumption. In the same models, we
also exploredthe associationbetween changes in urin-
aryarsenicbetweenvisitsandtheriskofmortalityfrom
cardiovascular disease.
We estimated the population attributable propor-
tion of mortality from cardiovascular disease asso-
ciated with higher concentrations of baseline well
arsenic concentration (>12 µg/L) using adjusted
hazard ratios estimated from Cox proportional
hazards regression (see equation B in fig 1).
44
Equation A 
   Time weighted arsenic concentration in µg/L= 
where Ci and Ti denote the well arsenic concentration and 
drinking duration for the ith well
Equation B 
where k is the number of exposure strata; Pj is the proportion of 
cause specific deaths in the jth exposure stratum; and HRj is the 
adjusted hazard ratio associated with j exposure stratum
1 –
     CiTi/      Ti
Σ
ΣΣ
k
j=1
Pj
HRj
Fig 1 | Equations for time weighted arsenic concentration and
population attributable proportion of mortality from
cardiovascular disease
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strap method with 1000 bootstrap samples.
As fish can accumulate organicarsenic, which could
influence total urinary arsenic concentration, rice can
containinorganicarsenicfromthesoil,andarsenichas
been related to increased risk of hypertension and
diabetes,
4546 we performed a sensitivity analysis to
evaluate whether the association between arsenic
exposure and risk of cardiovascular disease can be
attributable to arsenic from intakes of fish and rice, or
totheassociationofarsenicexposurewithdiabetesand
hypertension. The adjustment for creatinine might
influencethe relationbetweenarsenicanddisease out-
comes related to creatinine in cross sectional
studies.
4748 Although our study is a prospective cohort
study, we also conducted sensitivity analyses to assess
whether the association between urinary arsenic and
risk of cardiovascular disease was different when we
did not adjust for urinary creatinine. Given the sample
size, we had 80% power with α=0.05 to detect a hazard
ratio of 1.22 for cardiovascular disease mortality asso-
ciatedwith1SDdifferenceinbaselinewellarseniccon-
centration.
Secondary objectives: synergy between arsenic exposure and
cigarette smoking in mortality from heart disease
Weassessedthepresenceofsynergy(thatis,epidemio-
logical interaction or positive interaction on an addi-
tive scale) between arsenic exposure and cigarette
smoking by testing whether the joint effect from expo-
sure to both factors was greater than the sum of their
independent effects. We considered similar analysis
methodsandclassificationofsmokersusedinprevious
studies assessing synergy between arsenic exposure
and smoking in the risk of lung cancer and skin
lesions.
162049Rothmanhasdiscussedtheuseofrelative
excess risk for interaction (RERI) in assessing additive
interactions.
50 The additivity of risks associated with
two exposures corresponds to (R11−R00) = (R01−R00)
+( R 10−R00),whereR11 isthe risk ofdiseaseassociated
with having both exposures, R10 and R01 are the risks
of disease associated with one of the exposures along,
andR00istheriskofdiseaseassociatedwithabsenceof
bothexposures(backgroundrisk).Theequationcanbe
represented with risk ratios by dividing all the compo-
nents by R00 and assessing whether the relative excess
risk for interaction (relative excess risk for interaction,
RR11−RR10−RR01+1) is greater than zero and can be
used to evaluate if there is a positive departure from
additivity, or synergy, of the effects from two
exposures.
50 We used adjusted hazard ratios as surro-
gates of risk ratios in the following equation:
RERI≈HR11−HR10−HR01+1, where HR11 indicates
the hazard ratio for disease associated with a higher
level of arsenic exposure (moderate or high level) and
tobaccosmoking(ever,current,orpast)incomparison
to the a priori reference group with the lowest level of
arsenic exposure and never smoking; HR10 indicates
hazard ratio for a higher level of arsenic exposure
alone; and HR01 denotes hazard ratio for tobacco
smoking alone. We also estimated the attributable
proportion attributable to interaction as RERI/HR11
.
50 To increase power for interaction analyses, we
used thirds of arsenic exposure instead of quarters.
We estimated the relative excess risk for interaction
witharsenicexposureconsideredasa continuousvari-
able as follows:(e
β1+β2+β3)−(e
β1)−(e
β2)+1, where β1 is the
coefficientoftheeffectofperSDincreaseinthearsenic
exposure measure, β2 is the coefficient of tobacco
smoking, and β3 is the coefficient of the cross product
of per SD increase in arsenic exposure and tobacco
smoking.
495152 Confidence intervals of the relative
excess risk for interaction were estimated for statistical
inferences by using the standard delta method
describedby Hosmer and Lemeshow
5153 (for categori-
cal arsenic exposure) and bootstrap method with 1000
bootstrap samples (for continuous exposure
measure).
52 As the relative excess risk for interaction
is a measure of difference in excess relative risks, an
estimate over zero indicates presence of synergy of
two risk factors, and a 95% confidence interval that is
positive and excludes zero corresponds to P<0.05.
As some participants shared the same well, we used
robust standard errors for the proportional hazards
model
54 to account for the potentialinfluenceof corre-
lated exposure data. We also carried out sensitivity
analyses to exclude participants with any missing
data or imputed using the median values of the covari-
ates. All analysis was conducted with SAS 9.2
(SAS Institute, Cary, NC).
RESULTS
Weobserved77252personyearsduringthefollow-up
period.Therewere460deaths,ofwhich198werefrom
diseases of circulatory system (ICD-10 codes I00-I99),
accountingfor43%oftotalmortalityinthepopulation
and yielding a mortality rate of 256.3 per 100000 per-
son years. Among the 198 deaths from cardiovascular
disease, 85 were from cerebrovascular disease (codes
I60-I69);104werefromischaemicheartdisease(codes
I20-I25, n=71) or other forms of heart disease (codes
I30-I52, n=33), which included mostly deaths from
heartfailure(codesI50.0-I50.9,n=32)andventricular
tachycardia(codeI47,n=1);andninedeathswerefrom
pulmonary heart disease, hypertensive heart disease,
or multiple valve diseases (codes I08, I11, and I27).
Higher BMI and presence of diabetes were asso-
ciated with an increased risk of death from ischaemic
heart disease and other heart disease (table 1). There
wasnoassociationbetweeneducationallevelandmor-
tality from either diseases of the circulatory system
overall or any of the subtypes of cardiovascular dis-
ease. Diastolic and systolic hypertension were related
to an increased risk of death from diseases of the circu-
latory system overall and all subtypes of cardio-
vascular disease, and the associations were stronger
forcerebrovasculardisease.Participantswhowerecur-
rent smokers, had smoked for at least 20 years, or had
accumulatedatleast 10packyearsatbaselinewere1.6
to 1.9 times more likely to die from disease of circula-
torysystemand2.2to2.7timesmorelikelytodiefrom
ischaemic heart disease and other heart disease.
RESEARCH
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and cardiovascular disease mortality
We found an increased risk of mortality from diseases
of the circulatory system in people with high concen-
trations of well arsenic. The mortality rate for cardio-
vasculardiseasewas214.3per100000 personyearsin
people drinking water containing <12.0 µg/L arsenic
compared with 271.1 per 100000 person years in peo-
ple drinking water with ≥12.0 µg/L arsenic. Partici-
pants exposed to >148 µg/L (mean 265.7 µg/L) of
well arsenic were 1.47 (95% confidence interval 0.99
to 2.18) times more likely to die from diseases of the
circulatory system compared with their counterparts
who were exposed to <12 µg/L (model 2, table 2).
There was an increased risk of mortality from ischae-
mic heart disease and other heart disease in relation to
high concentrations of well arsenic, and a dose-
response relation remained after adjustment for BMI,
smokingstatus,educationalattainment,andchangesin
arsenic concentration between visits adjusted for urin-
ary creatinine in addition to age and sex (model 2,
P=0.0019 for trend). The hazard ratio was 1.29 (1.10
to 1.52, model 2) for a 1 SD increase in well arsenic
concentration (115 µg/L). A similar association was
observed between baseline well arsenic and mortality
from ischaemic heart disease; participants with
>148 µg/L of arsenic in well water were 1.94 (0.99 to
3.84)timesmorelikelytodiefromischaemicheartdis-
ease compared with those with <12 µg/L (model 2,
P=0.0294 for trend). The hazard ratio was 1.25 (1.03
to 1.52, model 2) for a 1 SD increase in well arsenic
concentration. On the other hand, there was no asso-
ciation between well arsenic and mortality from
cerebrovascular disease. Analysis results were similar
when we used time weighted arsenic concentration as
the exposure measure (see appendix 2 on bmj.com).
Table 1 |Relations between baseline risk factors and mortality from disease of circulatory system
Baseline risk
factors†
Person years
of follow-up
Diseaseofcirculatorysystem
Ischaemic heart disease and
otherformsofheartdisease* Ischaemic heart disease* Cerebrovascular disease
No of
deaths Hazard ratio
No of
deaths Hazard ratio
No of
deaths Hazard ratio
No of
deaths Hazard ratio
Body mass index (BMI):
12.0-18.5 29 767 88 1.06 (0.75 to 1.44) 39 0.95 (0.60 to 1.50) 25 0.96 (0.53 to 1.73) 45 1.16 (0.71 to 1.92)
18.5-22.0 29 829 61 1.00 31 1.00 19 1.00 26 1.00
22.1-40.0 15 834 44 1.29 (0.88 to 1.87) 30 1.74 (1.06 to 2.86) 24 2.34 (1.27 to 4.31) 13 0.88 (0.45 to 1.68)
Education (years):
0 34 070 93 1.00 49 1.00 27 1.00 40 1.00
1-5 23 060 45 0.80 (0.56 to 1.13) 24 0.79 (0.49 to 1.27) 18 1.04 (0.58 to 1.86) 19 0.80 (0.46 to 1.37)
6-16 20 094 60 1.18 (0.84 to 1.61) 31 1.12 (0.72 to 1.75) 26 1.58 (0.92 to 2.73) 26 1.21 (0.72 to 2.02)
Systolic blood pressure (mm Hg):
62-140 71 218 131 1.00 80 1.00 54 1.00 42 1.00
141-224 6046 67 3.22 (2.27 to 4.18) 24 2.03 (1.25 to 3.28) 17 2.03 (1.14 to 3.63) 43 5.39 (3.48 to 8.35)
Diastolic blood pressure (mm Hg):
60-90 70 240 151 1.00 90 1.00 62 1.00 53 1.00
91-139 7024 47 2.36 (1.70 to 3.27) 14 1.24 (0.70 to 2.20) 9 1.16 (0.57 to 2.37) 32 4.31 (2.82 to 6.61)
Diabetes:
No 75 972 185 1.00 97 1.00 67 1.00 80 1.00
Yes 1292 13 2.13 (1.26 to 3.62) 7 2.46 (1.15 to 5.23) 4 1.93 (0.72 to 5.14) 5 1.64 (0.67 to 4.02)
Cigarette or bidi‡ smoking:
Never 50 032 50 1.00 27 1.00 14 1.00 20 1.00
Past 4939 32 1.24 (0.71 to 2.18) 15 1.57 (0.66 to 3.71) 9 1.01 (0.35 to 2.90) 13 0.91 (0.41 to 2.01)
Current 22 250 115 1.74 (1.10 to 2.76) 61 2.23 (1.11 to 4.48) 47 1.87 (0.76 to 4.57) 52 1.65 (0.90 to 3.03)
Years of smoking cigarettes or bidi‡:
0 50 032 50 1.00 27 1.00 14 1.00 20 1.00
1-20 11 192 21 1.16 (0.61 to 1.98) 10 1.16 (0.46 to 2.92) 7 0.95 (0.31 to 2.92) 9 1.08 (0.49 to 2.36)
21-60 15 923 126 1.92 (1.13 to 3.01) 66 2.65 (1.24 to 5.67) 49 2.02 (0.79 to 5.17) 56 1.55 (0.81 to 2.96)
Pack years of cigarettes or bidi‡ smoked:
0 50 032 50 1.00 27 1.00 14 1.00 20 1.00
1-10 12 626 48 1.69 (1.00 to 2.62) 24 1.90 (0.90 to 4.05) 17 1.59 (0.61 to 4.15) 22 1.56 (0.82 to 2.97)
11-185 14 382 99 1.64 (1.00 to 2.59) 52 2.30 (1.06 to 4.95) 39 1.73 (0.70 to 4.30) 43 1.30 (0.69 to 2.43)
*Because deaths from other forms of heart disease were often consequence of previous ischaemic heart disease in our study population and patterns of hazard ratios were similar for
ischaemic heart disease and other forms of heart disease, we present hazard ratios for combined category and also for ischaemic heart disease separately.
†Categories of BMI based on conventional classification for underweight (<18.5), lower normal (18.5-22.0), and higher normal/overweight (>22.0). Categories of educational attainment based
on primary level (1-5 years) and secondary level or greater (>6 years) according to Bangladeshi educational system. Blood pressure categories based on established definitions for systolic
hypertension and diastolic hypertension. Categories of number of years smoked or pack years smoked based on cut points that were meaningful with easy interpretation.
‡Tobacco wrapped in tendu leaf.
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diabetes, and dietary intake of fish and rice did not
appreciablychangeeffectestimates(seeappendix3on
bmj.com). When participants with missing values for
BMI, education level, smoking status, and changes in
urinary arsenic between visits were excluded or
imputed by using the median level in the population,
the results were similar (data not shown).
We observed similar patterns of hazard ratios when
we used baseline urinary arsenic as the exposure vari-
able in the analyses (table 3). Baseline urinary arsenic
was related to an increased risk of mortality from dis-
eases of the circulatory system (model 2, P=0.0065 for
trend), and the association was stronger for the com-
bined category of ischaemic heart disease and other
heart disease (model 2, P=0.0001for trend). The effect
estimates did not materially change when we did not
adjust for urinary creatinine. For instance, the associa-
tion between urinary arsenic and mortality from heart
disease in increasing quarters of urinary arsenic con-
centrations were 1.00 (reference), 1.07 (0.57 to 2.03),
1.44(0.81to2.57),and2.08(1.09to3.95)(P=0.0001for
trend) (data not shown).
Spearman correlations of baseline urinary arsenic
with urinary arsenic measured at first and second fol-
low-up were both 0.65. Overall, total urinary arsenic
decreased by an average of 57.1 µg/g of creatinine
from baseline to first follow-up and then essentially
remained stable with an average increase of 3.2 µg/g
creatinine from first to second follow-up. The hazard
ratio was 1.18 (1.03 to 1.36) for total cardiovascular
disease mortality in relation to a 1 SD increase in
changes in urinary arsenic (240 µg per g of creatinine)
between visits, adjustment for age, sex, BMI, smoking
status, and baseline well arsenic concentration. The
number of deaths in extreme categories of changes in
urinary arsenic, however, was not enough for us to
evaluate the dose-responserelation for specific cardio-
vascular disease subtypes.
Secondary objectives: synergy between arsenic exposure
and cigarette smoking in mortality from heart disease
Although not significant, the risk of mortality from
heart disease seemed to be higher for people with
high level of arsenic exposure who had ever smoked
(fig 2). The risk of dying from ischaemic heart disease
andotherheartdiseaseassociatedwithmoderate(25.3-
114.0 µg/L, mean 63.5 µg/L) or high levels of arsenic
exposure (>114 µg/L, mean 228.8 µg/L) was consis-
tently higher in those who had ever smoked and espe-
cially in current smokers at baseline compared with
those who had never smoked. The joint effect of mod-
erateorhighlevelsofarsenicexposureandeversmok-
ing wasgreater thanthe sumoftheirindividualeffects,
with estimates of the relative excess risk due to inter-
action all greater than zero. In exploratory analyses,
when we further classified ever smokers into past and
currentsmokers,thesynergisticeffectbetweenmoder-
ateorhighlevelofarsenicexposureandcurrentsmok-
ingwasstronger(relative excessriskduetointeraction
2.21 (0.11 to 4.31; P=0.036) and 1.43 (0.02 to 3.61;
P=0.045), respectively) (fig 2). Figure 3 shows the sur-
vival curves by thirds of well arsenic and smoking sta-
tus in men and women. The synergistic effect between
smoking and arsenic exposure was similar in men and
women.Wefoundasimilarpatternofestimatesofrela-
tive excess risk due to interaction when we considered
Table 2 |Association between baseline concentrations of well arsenic (µg/L) and mortality from disease of circulatory system during follow-up
Hazard ratio (95% CI)
per 1 SD (115 µg/L) increase
Hazard ratio (95% CI) by mean (range) baseline concentrations
P for trend* 3.7 (0.1-12.0) 35.9 (12.1-62.0) 102.5 (62.1-148.0) 265.7 (148.1-864.0)
Personyearsoffollow-up 77 252 20 064 19 109 18 699 19 380 —
Disease of circulatory system
No of deaths 198 43 51 41 63 —
Model 1† 1.08 (0.96 to 1.22) 1.00 1.35 (0.91 to 2.00) 1.17 (0.76 to 1.79) 1.47 (0.99 to 2.18) 0.2153
Model 2‡ 1.11 (0.97 to 1.26) 1.00 1.21 (0.80 to 1.84) 1.24 (0.80 to 1.93) 1.46 (0.96 to 2.20) 0.1340
Ischaemic heart disease and other forms of heart disease
No of deaths 104 21 24 21 38 —
Model 1† 1.23 (1.05 to 1.43) 1.00 1.29 (0.71 to 2.34) 1.20 (0.65 to 2.22) 1.84 (1.06 to 3.17) 0.0072
Model 2‡ 1.29 (1.10 to 1.52) 1.00 1.22 (0.65 to 2.32) 1.35 (0.71 to 2.57) 1.92 (1.07 to 3.43) 0.0019
Ischaemic heart disease
No of deaths 71 14 16 15 26 —
Model 1† 1.19 (1.00 to 1.42) 1.00 1.31 (0.63 to 2.71) 1.31 (0.63 to 2.72) 1.89 (1.00 to 3.60) 0.0479
Model 2‡ 1.25 (1.03 to 1.52) 1.00 1.22 (0.56 to 2.65) 1.49 (0.70 to 3.19) 1.94 (0.99 to 3.84) 0.0294
Cerebrovascular disease
No of deaths 85 19 26 18 22 —
Model 1† 0.90 (0.73 to 1.11) 1.00 1.56 (0.88 to 2.79) 1.20 (0.64 to 2.26) 1.15 (0.59 to 2.22) 0.3099
Model 2‡ 0.89 (0.71 to 1.13) 1.00 1.35 (0.75 to 2.43) 1.20 (0.63 to 2.27) 1.07 (0.54 to 2.12) 0.3427
*Estimated with arsenic exposure variable as continuous variable in model.
†Adjusted for sex and baseline age (years).
‡Adjusted for sex and baseline age (years), BMI, smoking status (never, past, current), educational attainment (years), and changes in arsenic concentration adjusted for urinary creatinine
(µg per g of creatinine) between visits.
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There was a synergy between a 1 SD increase in well
arsenic concentration and ever smoking (0.38, 0.02 to
1.35),andthesynergywasstrongerwithcurrentsmok-
ing status (0.67, 0.08 to 1.86).
DISCUSSION
Interpretation of the results
In this prospective cohort study exposure to arsenic
from drinking water, as measured in well water and
urine, was associated with an increased risk of cardio-
vascular disease, in particular ischaemic heart disease
and other heart disease. Based on our observed esti-
mates, 28.9% (1.4% to 60.0%) of deaths from heart dis-
ease in this population can be attributable to arsenic
concentrations over 12 µg/L in well water. We found
asynergisticeffectbetweenarsenicexposureandcigar-
ettesmokingonmortalityfromischaemicheartdisease
and other heart disease, and this effect was apparent
even when arsenic exposure was moderate (25.3-
114.0 µg/L, mean 63.5 µg/L).
Comparison with other studies
Previous studies on mortality from cardiovascular dis-
ease in areas with low or moderate levels of arsenic
exposure from drinking water generated inconsistent
findings,
12-15probablybecausetheexposurerangewas
limited in detecting the association and the limitation
of using group level exposure asexposure level for the
individuals. For instance, using mean arsenic level at
the county level and National Center for Health
Statistics data, an ecological study in US counties
foundraisedstandardisedmortalityratiosformortality
from diseases of the arteries, arterioles, and capillaries
associated with water arsenic concentration > 20 µg/L
but no associations for mortality from any other
cardiovascular diseases.
12 The mortality from hyper-
tensive heart disease was raised in female but not in
male members of the Mormons in Millard County,
Utah, with <200 µg/L of arsenic in drinking water,
according to historical records of arsenic measure-
ments at the community level.
13 Ecological measures
of arsenic exposure are subject to large measurement
errors when there is variation in water concentrations
withinastudyregion.Astheeffectsoflowormoderate
levels of arsenic exposure on cardiovascular disease
risk are likely to be modest in magnitude, studies of
suchlevelsareparticularlysusceptibletomeasurement
errors in ascertainment of exposure, which, in most
cases, would lead to bias towards the null but could
also generate spurious associations under certain
conditions.
55 More recently, a cohort study in Bangla-
desh with well arsenic concentrations measured at
household level reported a dose-response relation
and an increased risk at exposures of 50-149 µg/L for
death from the combined category of cardiovascular
disease(hazardratio1.16,0.96to1.40).
33Arecenteco-
logical study in Spain reported raised mortality rates
for cardiovascular disease and coronary heart disease
associatedwitharsenicexposureat10-118µg/L.
15Our
study confirmed and extended observations in pre-
vious reports in that the validity of the findings is
Table 3 |Association between baseline urinary creatinine adjusted arsenic (µg/g of creatinine) and mortality from disease of circulatory system during follow-
up
Hazardratio(95%CI)per1
SD (282 µg per g of
creatinine) increase
Hazard ratio (95% CI) by mean (range) of baseline urinary creatinine adjusted of arsenic (µg/g of creatinine)
P for trend * 68.5 (6.6-105.9) 150.6 (106.0-199.0) 264.9 (199.1-351.8) 641.5 (351.9-1100)
Person years of
follow-up
73 835 18 818 18 355 18 161 18 501 —
Disease of circulatory system:
No of deaths 192 44 48 54 46 —
Model 1† 1.11 (0.99 to 1.24) 1.00 (ref) 1.07 (0.73 to 1.58) 1.35 (0.91 to 2.01) 1.30 (0.87 to 1.95) 0.0679
Model 2‡ 1.18 (1.04 to 1.33) 1.00 (ref) 1.15 (0.77 to 1.72) 1.56 (1.03 to 2.38) 1.55 (1.01 to 2.37) 0.0065
Ischaemic heart disease and other forms of heart disease:
No of deaths 101 22 25 25 29 —
Model 1† 1.16 (1.04 to 1.30) 1.00 (ref) 1.13 (0.66 to 1.95) 1.26 (0.70 to 2.25) 1.61 (0.93 to 2.78) 0.0071
Model 2‡ 1.26 (1.12 to 1.42) 1.00 (ref) 1.29 (0.74 to 2.27) 1.53 (0.83 to 2.82) 2.06 (1.14 to 3.72) 0.0001
Ischaemic heart disease:
No of deaths 69 17 18 17 17 —
Model 1† 1.08 (0.87 to 1.36) 1.00 (ref) 1.05 (0.56 to 2.00) 1.13 (0.58 to 2.21) 1.28 (0.65 to 2.51) 0.3878
Model 2‡ 1.22 (0.99 to 1.49) 1.00 (ref) 1.29 (0.66 to 2.51) 1.47 (0.72 to 3.01) 1.90 (0.91 to 3.98) 0.0585
Cerebrovascular disease:
No of deaths 82 20 20 27 15 —
Model 1† 1.03 (0.82 to 1.29) 1.00 (ref) 0.96 (0.52 to 1.77) 1.47 (0.82 to 2.65) 0.96 (0.49 to 1.88) 0.8062
Model 2‡ 1.06 (0.84 to 1.35) 1.00 (ref) 0.96 (0.52 to 1.79) 1.60 (0.88 to 2.90) 1.03 (0.53 to 2.03) 0.6230
*Estimated with arsenic exposure variable as continuous variable in model.
†Adjusted for sex and baseline age (years).
‡Adjusted for sex and baseline age (years), BMI, smoking status (never, past, current), educational attainment (years), and changes in arsenic concentration adjusted for urinary creatinine
(µg per g of creatinine) between visits.
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fact that the outcome, potential confounders, effect
modifiers, and well arsenic and urinary arsenic were
all measured at the individual level.
Consistent with retrospective cohort and ecological
studies of mortality from cerebrovascular disease in
Chile, Taiwan, and Spain,
111556 we found no associa-
tion between arsenic exposure and mortality from
cerebrovasculardisease.AcrosssectionalstudyinTai-
wan,however,reportedapositiveassociationbetween
arsenic exposure and the prevalence of cerebro-
vasculardisease.
57Theconflictingresultsinthestudies
could be partly because of the heterogeneity of the
causes of cerebrovascular disease. The distribution of
ischaemic stroke and haemorrhagic stroke might be
different in studies of mortality and prevalence of
cerebrovascular disease. Future larger studies with
subtypes of cerebrovascular disease are needed to
further assess the association.
We found that changes in urinary arsenic over time
were positively associated with the risk of mortality
from total cardiovascular disease. A study in Chile
has suggested that the latency required for arsenic
exposure to have an influence on the risk of cardio-
vascular disease was relatively shorter than that for
the risk of cancer.
11 With longer follow-up, we will be
abletocharacterisethisassociationandstudytheinflu-
ence of changes in arsenic exposure on the risk of sub-
types of cardiovascular disease in the future.
Interaction between arsenic exposure and cigarette
smoking
The hypothesis that cigarette smoking increases sus-
ceptibility to the cardiovascular effects of arsenic is
well supported by previous studies on cancer and skin
lesions.
16-2058 Cigarette smoking has been associated
with a lower methylation capacity of arsenic, as indi-
catedbyahigherratioofurinarymonomethylarsonate
to dimethylarsinate in smokers.
59 Moreover, tobacco
smoking can increase the requirement of folate, a criti-
cal cofactor in one-carbon metabolism, a process
through which arsenic is enzymatically methylated.
Takentogether,cigarettesmokingislikelytoinfluence
arsenictoxicityandshouldbetakenintoconsideration
in studiesof lower levelsof arsenicexposure.Thecon-
sideration of smoking is more important for outcomes
such as lung cancer and cardiovascular disease, for
which arsenic might not be a necessary cause, as
opposed to skin lesions. The synergistic effect
observed in our study provides evidence of the pre-
sence of individuals who would experience a high
risk of ischaemic heart disease and other heart disease
only if they are exposed to both cigarette smoking and
arsenic exposure at concentrations as low as 25.3-
114.0 µg/L. The corresponding estimate for the attri-
butable proportiondue to interaction is 59% (13.8% to
100%), indicating that as much as 59% of deaths from
heart disease among smokers with moderate level of
arsenic exposure might be attributable to the synergis-
tic effect of these two exposures. This finding has
important public health implications in that smoking
cessation or reduction in exposure to arsenic can lead
to a greater than expected reduction in mortality from
heart disease.
Potential underlying mechanisms
The mechanisms by which arsenic leads to cardio-
vascular disease are not clear. Several animal studies
have suggested that arsenic can induce
atherosclerosis.
60-62 The induction of oxidative stress
by arsenic can influence gene expression, inflamma-
tory responses, and endothelial nitric oxide
homoeostasis,
63 which play an important role in main-
tainingvasculartone.
64Ina crosssectionalstudyofthe
baseline data, we observed a positive association
between arsenic exposure and high pulse pressure,
45
a consequence of arteriosclerosis and arterial
stiffness.
6566Severalinvitrostudiessuggestthatarsenic
promotes inflammatory activity
6167 and endothelial
cell remodelling.
68 Among cases of arsenic induced
skin lesions in our study population, we found a posi-
tive association between arsenic exposure and plasma
concentrations of soluble cell adhesion molecules,
markers of endothelial dysfunction for risk of cardio-
vasculardisease.
69Futurestudiesinhealthyindividuals
with preclinical phenotypes for vascular inflammation
and endothelial dysfunction relevant for cardio-
vascular disease are needed to clarify the underlying
mechanisms.
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  0.1-25.2
  25.3-114.0
  114-864.0
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Never smoked
  0.1-25.2
  25.3-114.0
  114-864.0
Past smoker
  0.1-25.2
  25.3-114.0
  114-864.0
Current smoker
  0.1-25.2
  25.3-114.0
  114-864.0
1 (reference)
0.57 (0.19 to 1.70)
1.53 (0.65 to 3.59)
1.52 (0.58 to 4.02)
2.65 (1.03 to 6.81)
2.76 (1.10 to 6.92)
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0.55 (0.19 to 1.69)
1.53 (0.65 to 3.60)
1.81 (0.52 to 6.34)
1.66 (0.43 to 6.40)
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1.50 (0.54 to 4.15)
3.28 (1.26 to 8.53)
3.45 (1.32 to 8.98)
1.56 (0.05 to 3.14), P=0.010
0.71 (0.02 to 2.40 ), P=0.052
2.21 (0.11 to 4.31), P=0.036
1.43 (0.02 to 3.61), P=0.045
0123456
Arsenic concentration (µg/L) Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Relative excess risk
due to interaction
Fig 2 | Joint effect of cigarette smoking and concentrations of well arsenic at baseline on
mortality from ischaemic heart disease and other heart disease. Hazard ratios adjusted for sex
and baseline age (years), BMI, education, and changes in urinary creatinine adjusted arsenic
(µg/g of creatinine) between visits
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Unique features of the present study include the avail-
ability of data on arsenic exposure measured in both
urine and water, the use of repeat measurements of
totalurinaryarsenictomeasureinternaldoseofarsenic
exposure and to track changes in exposure levels over
time, and the information on cigarette smoking. In a
random 10% of participants, inorganic arsenic (As
V
and As
III) and its metabolites monomethylarsonate
and dimethylarsinate accounted for 96% of total urin-
aryarsenic,whereasarsenobetaineandarsenocholine,
derived mainly from dietary intakes of certain marine
fish, together accounted for 3%.
70 Thus well arsenic,
which has a correlation of 0.70, 0.61, and 0.57 with
total urinary arsenic, urinary dimethylarsinate, and
urinary monomethylarsonate concentration,
respectively,
70 was clearly the main source of arsenic
in the urine.
Several potential limitations, however, should also
be noted. Firstly, we did not consider individual meta-
bolitesofarsenicin urineorbloodandthereforecould
not assess susceptibility from arsenic methylation
capacity. We are currently assessing the role of arsenic
metabolites in modifying the risk of disease in a case-
cohort study. Secondly, the study results might not be
generalisabletootherpopulationswithadifferentpro-
file of risk factors for cardiovascular disease that might
interactwitharsenicexposureinrisk.Inparticular,the
study population consisted of married men and
women, who were mostly lean, with a mean BMI of
18.9. The choice of recruiting married men and
women, however, helped the retention of the partici-
pantsinfollow-upandshouldenhanceinternalvalidity
of the findings. Future studies are needed to evaluate
potential effect modifications by specific nutritional
factors that are related to arsenic metabolism, such as
folate and selenium. Lastly, our study is an observa-
tional study and might be susceptible to unmeasured
confounding. Individuals’ choice of well was largely
based on geographical convenience, however, and
well arsenic concentration was not well known
among the study population before recruitment.
242538
Though we did not collect information on hyperlipi-
daemia, available literature does not suggest a positive
associationbetween arsenic exposuresand cholesterol
profile.
6271 Adjustment for other established risk fac-
tors for cardiovascular disease did not change results
appreciably. We would therefore expect the impact of
residual confounding to be relatively minor.
Conclusions
In conclusion, in this prospective cohort analysis, we
found a dose-response relation between arsenic expo-
sure and mortality from cardiovascular disease, espe-
cially heart disease, at a much lower level of arsenic
exposurethanpreviouslyreported.Therewasasyner-
gistic effect between cigarette smoking and arsenic
exposure at moderate or high levels on mortality
from ischaemic heart disease and other heart disease.
These findings suggest the cardiovascular effects of
arsenic exposure at moderate levels, which is further
potentiated by smoking.
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Fig 3 | Multivariate adjusted (education, age, BMI, changes in urinary arsenic over time) survival curves for ischaemic heart
disease and other heart disease by baseline concentrations of well arsenic (low, medium, and high), sex, and baseline
smoking status. Drop in survival curves around year 8 was because all participants who were alive at the end of third (final)
follow-up visit were censored at date of that visit
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WHAT IS ALREADY KNOWN ON THIS TOPIC
High levels of exposure to arsenic (>500 µg/L) in drinking water have been related to an
increased risk of cardiovascular disease
WHAT THIS STUDY ADDS
Therewas a dose-response relationbetweenarsenicexposure,measuredatbaselineinboth
water and urine, and subsequent mortality from cardiovascular disease, especially heart
disease, in a Bangladeshi population with a moderate level of exposure
There was a synergistic effect between cigarette smoking and arsenic exposure on mortality
from heart disease
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